Postoperative PainNCT07779551
Comparison of Two Drugs Bupivacaine and Ropivacaine for Postoperative Analgesia in Bilateral Superficial Cervical Plexus Block After Thyroidectomy
A study testing Group 1 will receive 10ml of 0.25% bupivacaine and Group 2 will receive 10ml of 0.25% ropivacaine on each side. in people with Postoperative Pain, run by Sargodha Medical College at 1 site in Pakistan.
Trial summary
There is significant difference between bupivacaine and ropivacaine in terms of postoperative pain assessment in patients undergoing total thyroidectomy with bilateral superficial cervical plexus block. Read more about this study
- Who is it for?
- Ages 20 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Postoperative Pain
- What is being tested?
- Group 1 will receive 10ml of 0.25% bupivacaine and Group 2 will receive 10ml of 0.25% ropivacaine on each side.
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 94 participants
- Where
- 1 sitePakistan
- Study dates
- 22 Jan 2026to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age range:20-40 years.
- Both male and female individuals.
- Patients classified as American Society of Anesthesiologists (ASA)I-II.
- Patients scheduled for elective total thyroidectomy under general anesthesia
Who cannot join
- Patient Refusal
- Hypothyroidism,Hyperthyroidism,Retrosternal goiter
- Premedication with preoperative analgesics
- Excessive alcohol intake,Electrolyte imbalance
- Pregnancy or lactation
- Coagulation disorders
- Additional surgical intervention
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site
Dr Faisal Masood teaching Hospital Sargodha
Sargodha, Punjab Province, 40100
About this study
Official title: Comparison of Postoperative Analgesia Using Bupivacaine vs Ropivacaine With Bilateral Superficial Cervical Plexus Block After Thyroidectomy
There is significant difference between bupivacaine and ropivacaine in terms of postoperative pain assessment in patients undergoing total thyroidectomy with bilateral superficial cervical plexus block.
- Conditions
- Postoperative Pain
- Being tested
- Group 1 will receive 10ml of 0.25% bupivacaine, Group 2 will receive 10ml of 0.25% ropivacaine on each side.
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group 1 will receive 10ml of 0.25% bupivacaineProcedure or surgery
After placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure.
Group 2 will receive 10ml of 0.25% ropivacaine on each side.Procedure or surgery
After placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure
| Study group | Role | What they receive |
|---|---|---|
| Group 1 will receive 10ml of 0.25% bupivacaine on each side, | Other | Not described Receives: Procedure: Group 1 will receive 10ml of 0.25% bupivacaine |
| Group 2 will receive 10ml of 0.25% ropivacaine on each side | Other | Not described Receives: Procedure: Group 2 will receive 10ml of 0.25% ropivacaine on each side. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative pain
Measured: 24 hours post surgery
time to the first request for analgesia
Measured: 24 hours postoperatively
Block-related complications
Measured: immediately after the intervention/procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2026
- Study start22 Jan 2026
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 94 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sargodha Medical College
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07779551
- Sponsor's protocol ID
- SMC-ANS-2025-006
- Status last verified
- Aug 2026
- First submitted
- 15 Aug 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Postoperative Analgesia Using Bupivacaine vs Ropivacaine With Bilateral Superficial Cervical Plexus Block After Thyroidectomy
- ClinicalTrials.gov ID
- NCT07779551
- Acronym / sponsor ID
- SMC-ANS-2025-006
- Conditions
- Postoperative Pain
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 94 participants (estimated)
- Lead sponsor
- Sargodha Medical CollegeUniversity, hospital or other
- Study start
- 22 Jan 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 21 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There is significant difference between bupivacaine and ropivacaine in terms of postoperative pain assessment in patients undergoing total thyroidectomy with bilateral superficial cervical plexus block.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1 will receive 10ml of 0.25% bupivacaine on each side, | Other | Procedure: Group 1 will receive 10ml of 0.25% bupivacaine |
| Group 2 will receive 10ml of 0.25% ropivacaine on each side | Other | Procedure: Group 2 will receive 10ml of 0.25% ropivacaine on each side. |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Age range:20-40 years.
- Both male and female individuals.
- Patients classified as American Society of Anesthesiologists (ASA)I-II.
- Patients scheduled for elective total thyroidectomy under general anesthesia
Key exclusion criteria (7 listed)
- Patient Refusal
- Hypothyroidism,Hyperthyroidism,Retrosternal goiter
- Premedication with preoperative analgesics
- Excessive alcohol intake,Electrolyte imbalance
- Pregnancy or lactation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group 1 will receive 10ml of 0.25% bupivacaineAfter placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure. | Procedure or surgery | Group 1 will receive 10ml of 0.25% bupivacaine on each side, |
| Group 2 will receive 10ml of 0.25% ropivacaine on each side.After placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure | Procedure or surgery | Group 2 will receive 10ml of 0.25% ropivacaine on each side |
Primary outcome
Postoperative pain
Time frame: 24 hours post surgery
time to the first request for analgesia
Time frame: 24 hours postoperatively
Block-related complications
Time frame: immediately after the intervention/procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
Related trials for Postoperative Pain
Recruiting
Conditioned Open Label Placebo for Postoperative Pain Management
Pain, Postoperative
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Not yet recruiting
Post-operative Pain and Clinical Outcome After Single-cone Obturation With a Calcium Silicate-based Versus Epoxy Resin Sealer
Post Operative Pain, Acute, Irreversible Pulpitis (Toothache)
Not yet recruiting
Adding Different Doses of Dexmedetomidine to Bupivecaine in Erector Spinae Plane Block
Postoperative Pain in Lumbar Spine Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Group 1 will receive 10ml of 0.25% bupivacaine and Group 2 will receive 10ml of 0.25% ropivacaine on each side. in people with Postoperative Pain, run by Sargodha Medical College at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative pain (time frame: 24 hours post surgery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026; AzTrials last refreshed its copy on 8 Nov 2026.